The era of the “Just Say No” campaign appears to be over. Over the weekend, President Donald Trump signed an executive order to accelerate the availability of certain psychedelics as treatments for mental health conditions. The order includes a $50 million allocation and directs the Food and Drug Administration (FDA) to expedite reviews to hasten their approval.
During the signing event, Trump humorously addressed the assembled group—including administration officials, a former Navy SEAL, and podcaster Joe Rogan—asking, “Can I have some, please?”
On Wednesday, the Trump administration took further action by downgrading medical marijuana from the highest tier of controlled substances. The administration also urged the Drug Enforcement Administration (DEA) to reclassify recreational marijuana, signaling a significant shift in federal drug policy.
Trump’s Drug Policy: A New Era for the GOP
The president’s more lenient approach to certain mind-altering substances contrasts sharply with his administration’s hardline stance on fentanyl. While maintaining a militaristic strategy against opioids, these recent moves on “softer” drugs could herald a transformative period for Republican drug policy—and American drug policy as a whole.
Critics Warn of Unprecedented Consequences
Kevin Sabet, CEO of the anti-legalization advocacy group Smart Approaches to Marijuana, condemned the administration’s actions in a statement:
“With this imminent move, we are now confronted with the most pro-drug administration in our history. Policy is now being dictated by marijuana CEOs, psychedelics investors, and podcasters in active addiction—it is a travesty and injustice to the American people of unprecedented proportions. The marijuana industry is the new Big Tobacco, and President Trump is welcoming them to the homes of families across this country with open arms.”
Related articles
Opinion: Marty Makary misunderstood something fundamental about the FDA
On Tuesday, Food and Drug Administration Commissioner Marty Makary resigned from his position, leaving a vacancy at the top of the agency to match the...
Journalists Unpack Latest on Vaccines, Vaping, and TrumpRx
KFF Health News chief Washington correspondent Julie Rovner discussed federal policy on vaccine research, vaping, and drug access on Science Friday on...
STAT+: FDA drug center head Tracy Beth Høeg leaves as agency faces leadership vacuum
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
Kratom use is on the rise in the US
A national study of kratom use in the US found rising popularity among young adults, and it is linked to addiction and mental health issues, according...
STAT+: A political contest in the U.K. could shake up drug pricing
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Mail-order abortion pills are legal (for now)
In a discussion about the best fruits, my STAT colleague Alexa Lee and I agreed that peaches have been mid in recent years. Is this just a New York Ci...
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...